Streetbeat News

Earnings

CMRX

Chimerix (NASDAQ:CMRX) reported Q2 EPS of $(0.21), beating the estimate of $(0.24) by 12.5%. However, the company's sales of $26.00K missed the estimate of $230.00K by 88.7%. This represents a 94.09% decrease from the same period last year. The company has $233M available to fund operations.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 1:04 pm

SHOP

Shopify Inc. (NYSE:SHOP) reported better-than-expected Q2 earnings and sales results, with a 31% YoY increase in revenue to $1.69 billion. The company expects Q3 revenue to grow at a low-twenties percentage rate YoY. Following the announcement, Piper Sandler and Barclays raised their price targets on Shopify. Despite the positive results, Shopify shares fell 1.1% in pre-market trading.

Portfolio Pulse from Lisa Levin

August 04, 2023 | 1:04 pm

OSA

ProSomnus reported Q2 earnings per share (EPS) of $(0.01), beating the estimate of $(0.31). The company's sales also surpassed the estimate, coming in at $6.90M against the expected $6.56M.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 1:04 pm

PGTI

PGT Innovations has projected its Q3 revenue to be between $385M and $405M, which is in line with the estimated $386M.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 1:04 pm

HGV

Hilton Grand Vacations has reiterated its FY23 guidance for Adjusted EBITDA of $1.09B-$1.12B. The company remains well-positioned to generate sustainable free cash flow and deliver shareholder returns.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 1:04 pm

SNSE

Sensei Biotherapeutics reported Q2 losses of $(0.31) per share, beating the analyst consensus estimate of $(0.33) by 6.06%. This represents an 8.82% improvement over the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 1:03 pm

BCYC

Bicycle Therapeutics reported Q2 cash and cash equivalents of $340.4M.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 1:03 pm

MORF

Morphic Holding reported Q2 losses of $0.92 per share, missing the analyst consensus estimate of $0.87 by 5.75%. This represents a 235.29% decrease from the same period last year. The company has over $730 million in cash and equivalents, extending its cash runway into the second half of 2027.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 1:03 pm

VMC

Vulcan Materials Company (VMC) has projected its net earnings attributable to the company for the fiscal year 2023 to be between $855 million and $935 million.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 1:03 pm

ABUS

Arbutus Biopharma reported Q2 losses of $(0.10) per share, beating the analyst consensus estimate of $(0.12) by 16.67%. However, the company's quarterly sales of $4.65 million missed the analyst consensus estimate of $5.02 million by 7.35%, marking a 67.34% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 1:03 pm